BCR and diffuse large B-cell lymphoma: We show that PCNSL can be clearly distinguished from systemic DLBCL, having distinct expression profiles, IG expression, and translocation patterns, as well as specific combinations of genetic alterations that are characterized by genomic instability, BCR activation, and most importantly, oncogenic TLR and NFκB signaling, which should be in the focus of future drug development.